In 2025, Choroideremia Research Foundation (CRF) acquired all Spark Therapeutics, Inc. assets related to its SPK- 7001 gene therapy for treating Choroideremia (AAV2-hCHM-101) following the decision to discontinue the program. The acquired assets include intellectual property rights, biological materials, orphan drug designations, Phase I/II clinical trial data, and Natural History Study data.
Read the full article: Choroideremia Research Foundation Acquires Spark Therapeutics, Inc., CHM Gene Therapy Assets, Advances Data Analysis //
Source: https://www.einpresswire.com/article/885237989/choroideremia-research-foundation-acquires-spark-therapeutics-inc-chm-gene-therapy-assets-advances-data-analysis